Allergan recently announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market Natrelle INSPIRA SoftTouch breast implants, offering women undergoing breast reconstruction, augmentation, or revision surgery a new medium firmness gel, or cohesive, implant option. With this addition the Natrelle line of breast implants is the only implant line with three levels of cohesive gel.
“Adding Natrelle INSPIRA SoftTouch breast implants to our already robust line of offerings gives Allergan the most extensive variety of implants in the industry and provides doctors with a wide range of options,” says David Nicholson, Chief R&D Officer of Allergan plc. “Now, the INSPIRA line of breast implants helps physicians to better meet diverse, patient-specific needs based on available breast tissue and desired outcomes. We’re delighted to have this offering available in the U.S. since they are so popular with doctors and patients internationally.”
The FDA approval of Natrelle INSPIRA SoftTouch breast implants marks the most recent addition to the broad portfolio of currently available Natrelle products in the U.S. Natrelle offers implants with differing gel firmness for differing levels of form stability.
“I am excited to have yet another option available within the Natrelle portfolio. This is one of the most exciting times in the history of breast surgery and what a great time for women, who are looking to have augmentation or have to have reconstruction,” says Dr. Allen Gabriel of PeaceHealth Plastic Surgery. “My patients now have so many options available to them thanks to companies like Allergan who are supporting ongoing research and innovation in this area.”